Stifel raised its price target on Kamada Ltd. to $12.00 from $11.00, maintaining a Buy rating. The stock trades at $7.68, according to the report.
Kamada reported third-quarter revenues of $52 million, up 11%. Growth came from specialty plasma products including Kedrab for rabies prophylaxis and Varizig for varicella, plus distribution revenue from MENA expansion and new biosimilars.
The company raised 2026 guidance to revenues of $205 million to $208 million, representing 14% growth, and adjusted EBITDA of $52 million to $54 million, a 26% increase.
Kamada ended the third quarter with $75.3 million in cash and equivalents. Year-to-date dividends totaled $32 million, reflecting a 2.35% dividend yield.
The company launched two new biosimilar products, Ustekinumab-Kamada and Enoxaparin-Kamada, bringing its biosimilar portfolio to four commercialized products. StoneX analysts reiterated a Buy rating with a $15.00 price target following a U.S. Centers for Disease Control advisory about rising human rabies exposure cases. Kamada confirmed sufficient supply of KedRAB to meet heightened demand.
Investors tracking KMDA should monitor third-quarter earnings execution against the raised 2026 guidance and biosimilar product uptake.